2-(2-Phenylacetamido)acetic acid

2-(2-Phenylacetamido)acetic acid (CAS No.: 500-98-1) is an endogenous small-molecule metabolite derived from gut microbiota, formed through microbial conversion of phenylalanine to phenylacetic acid followed by hepatic glycine conjugation, and is commonly classified as a host–microbiome co-metabolite with emerging relevance in cardiovascular research. This compound has been reported to function as an agonist of the β2-adrenergic receptor (β2AR), implicating it in adrenergic signaling pathways that regulate cardiac stress responses, cell survival, and metabolic adaptation. Mechanistic studies indicate that it modulates β2AR-dependent signaling cascades involved in cardioprotection, including attenuation of hypoxia-induced apoptosis in cardiomyocytes and reduction of myocardial infarct size in ischemia–reperfusion injury models, supporting a role in mitigating cardiac damage under stress conditions. In vitro activity is typically observed at micromolar concentrations, where it influences cellular viability and apoptosis-related pathways in cardiac cell systems. Additionally, altered systemic levels of this metabolite have been associated with pharmacologically induced metabolic disturbances, highlighting its potential utility as a biomarker in toxicological and metabolic studies. 2-(2-Phenylacetamido)acetic acid is therefore widely used in experimental models to investigate gut microbiota–host interactions, β2AR-mediated signaling, and cardiovascular pathophysiology, as well as in drug discovery efforts aimed at modulating cardioprotective pathways, with concentrations and dosing regimens tailored to specific experimental designs.